Olink Proteomics

Executive Summary

Olink Proteomics, now a part of Thermo Fisher Scientific following its acquisition in 2023, is a leader in high-throughput proteomics with its proprietary Proximity Extension Assay (PEA) technology. PEA enables multiplexed analysis of up to 5,400 proteins with exceptional specificity and sensitivity from minimal sample volumes, making it a critical tool for biomarker discovery and clinical development. The company serves academic researchers and pharmaceutical partners, accelerating the translation of protein biomarkers into diagnostics and therapeutics. Integration with Thermo Fisher's broader life sciences portfolio enhances Olink's commercial reach and operational capabilities, positioning it for sustained growth in the rapidly expanding proteomics market. With a strong technology moat and established customer base, Olink is well-placed to drive precision medicine initiatives globally.

Upcoming Catalysts (preview)

• Q3 2026Launch of next-generation PEA panels with expanded protein coverage and improved throughput80% success
• Q4 2026Regulatory clearance of Olink's technology for clinical diagnostic use (e.g., IVD certification)70% success
• Q2 2026Major pharma partnership for protein biomarker-based patient stratification in oncology trials90% success